Obinutuzumab

• AVO-CLL: a phase III multicenter, randomized, open-label, clinical trial comparing efficacy and safety of acalabrutinib in combination with … Recruiting
  2023-508423-13-00 Phase III 1 country Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting
  2023-505436-35-00 Phase III 6 countries Lysarc
• FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab … Recruiting
  2022-501554-11-00 Phase II 1 country French Innovative Leukemia Organization
• Phase III trial comparing local radiotherapy alone or with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial. Recruiting
  2022-502775-29-01 Phase III 1 country Fondazione Italiana Linfomi Onlus
• A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory… Recruiting
  2023-503206-37-00 Phase III 4 countries F. Hoffmann-La Roche AG
• First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl-… Recruiting
  2023-510431-11-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Che… Recruiting
  2023-504264-41-00 Phase I/II 8 countries F. Hoffmann-La Roche AG
• Early Stage Follicular LymphOma and RadioTherapy PLUS anti-CD20 Antibody Recruiting
  2023-509278-41-00 Phase III 1 country Universitaetsklinikum Heidelberg AöR
• Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants Wi… Recruiting
  2023-504599-10-00 Phase II 6 countries AbbVie Deutschland GmbH & Co. KG
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis an… Recruiting
  2023-505825-15-00 Phase II 4 countries F. Hoffmann-La Roche AG
• A Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent … Recruiting
  2023-505625-14-00 Phase I (FiH) 8 countries F. Hoffmann-La Roche AG
• STEP-WISE COMBINATION OF OBINUTUZUMAB, VEMURAFENIB AND COBIMETINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) PREVIOUSLY TREATED WITH PURINE… Ended
  2024-520121-36-00 Phase II 1 country Universita' Degli Studi Di Perugia
• A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination with Intravenously… Ended
  2024-512147-23-00 Phase II/III 3 countries AbbVie Deutschland GmbH & Co. KG
• First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in… Ended
  2022-502808-72-00 Phase II 2 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended
  2023-506906-38-00 Phase III 17 countries AbbVie Deutschland GmbH & Co. KG
• A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i… Ended
  2023-506948-17-00 Phase III 9 countries BeOne Medicines AG
• A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate pol… Ended
  2024-513949-37-00 Phase II 2 countries Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
• A Phase III Open-Label Trial of Acalabrutinib Plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocyti… Ended
  2023-505866-27-00 Phase III 5 countries Astrazeneca AB
• OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated ma… Ended
  2024-512634-15-00 Phase I/II 2 countries LYSARC
• Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph… Ended
  2024-511636-27-00 Phase III 1 country Fondazione Italiana Linfomi Ets
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with Systemic Lupus Erythematosus (ALLEGORY) Ended
  2023-504774-38-00 Phase III 5 countries F. Hoffmann-La Roche AG
• A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy Ended
  2023-506525-11-00 Phase III 4 countries F. Hoffmann-La Roche AG
• A Study to Evaluate the Efficacy and Safety of Glofitamab in Combination with Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination w… Ended
  2023-506899-27-00 Phase III 6 countries F. Hoffmann-La Roche AG
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended
  2022-500439-35-00 Phase III 11 countries University Of Cologne

Showing 25–48 of 65 trials